In last trading session, NeuroSense Therapeutics Ltd (NASDAQ:NRSN) saw 96203.0 shares changing hands with its beta currently measuring 1.29. Company’s recent per share price level of $1.12 trading at -$0.07 or -5.84% at ring of the bell on the day assigns it a market valuation of $25.86M. That closing price of NRSN’s stock is at a discount of -108.04% from its 52-week high price of $2.33 and is indicating a premium of 54.46% from its 52-week low price of $0.51. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.35 million shares which gives us an average trading volume of 292.47K if we extend that period to 3-months.

NeuroSense Therapeutics Ltd (NASDAQ:NRSN) trade information

Upright in the red during last session for losing -5.84%, in the last five days NRSN remained trading in the red while hitting it’s week-highest on Monday, 01/06/25 when the stock touched $1.12 price level, adding 13.17% to its value on the day. NeuroSense Therapeutics Ltd’s shares saw a change of -6.84% in year-to-date performance and have moved -6.84% in past 5-day. NeuroSense Therapeutics Ltd (NASDAQ:NRSN) showed a performance of 7.49% in past 30-days. Number of shares sold short was 0.32 million shares which calculate 2.01 days to cover the short interests.

NeuroSense Therapeutics Ltd (NRSN) estimates and forecasts

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -7.06% during past 5 years.

NeuroSense Therapeutics Ltd (NASDAQ:NRSN)’s Major holders

ARMISTICE CAPITAL, LLC is the top institutional holder at NRSN for having 1.58 million shares of worth $1.77 million. And as of 2024-06-30, it was holding 10.2822 of the company’s outstanding shares.

The second largest institutional holder is MEITAV INVESTMENT HOUSE LTD, which was holding about 40000.0 shares on 2024-06-30. The number of shares represents firm’s hold over 0.2597 of outstanding shares, having a total worth of $44800.0.